NK cell production platform technology

Completely closed NK cell production platform for high log scale expansion and differentiation of functional oNKord® NK cells


Glycostem has focused on the development of a highly reliable and reproducible GMP-compliant process for the ex vivo generation of highly pure and functional oNKord® from cryopreserved “off-the-shelf" umbilical cord blood (UCB) products. Glycostem has developed a closed, large-scale expansion and differentiation process in which stem cells from Umbilical Cord Blood – UCB are first expanded and in two following steps differentiated to mature NK cells.


Glycostem carefully selected the stem cell source. Glycostem produces oNKord® from Cord Blood which has many advantages over other sources:

  • UCB is a rich source of stem cells
  • Usage of UCB is not restricted by ethical considerations.
  • UCB is not scarce and commercially available at excellent quality, reliability and prices.

Subscribe to our newsletter

If you subscribe you agree to the Privacy Notice of Glycostem Therapeutics B.V. as found on the website.